Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Strategies Pricing Debate Cancer

Curbing Cancer Drug Costs: Lartruvo Vial Sizes Designed To Reduce Waste

  • Analysis

Executive Summary

Lilly researchers used real-world data to identify a second vial size for Lartruvo that could reduce waste by nearly 87% compared to offering only a single large-size vial.

You may also be interested in...



AmerisourceBergen Oncology Drug Repackaging Program Draws $260m Fine

Now-defunct AmerisourceBergen subsidiary inappropriately repackaged oncology support drugs like Neupogen and Procrit in pre-filled syringes, violating the law and prompting safety concerns, Department of Justice announced.

Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas

Accelerated filing was supported by trial of patients with 25 subtypes of soft tissue sarcoma and confirmatory study will span 50 kinds.

Cancer Drug "Oversized" Single-Dose Vials Waste Money, Need Rethinking – Article

Amgen, Takeda and Merck push back against article’s conclusions on the waste generated by current vials for infused drugs.

Table

View full table

Topics

Related Companies

Tags:
Pricing Strategies Pricing Debate Cancer
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS120672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By